Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection.

Hartlage AS, Murthy S, Kumar A, Trivedi S, Dravid P, Sharma H, Walker CM, Kapoor A.

Nat Commun. 2019 Mar 7;10(1):1113. doi: 10.1038/s41467-019-09105-0.

2.

Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model.

Trivedi S, Murthy S, Sharma H, Hartlage AS, Kumar A, Gadi SV, Simmonds P, Chauhan LV, Scheel TKH, Billerbeck E, Burbelo PD, Rice CM, Lipkin WI, Vandegrift K, Cullen JM, Kapoor A.

Hepatology. 2018 Aug;68(2):435-448. doi: 10.1002/hep.29494. Epub 2018 May 21.

PMID:
28859226
3.

Mouse models of acute and chronic hepacivirus infection.

Billerbeck E, Wolfisberg R, Fahn√łe U, Xiao JW, Quirk C, Luna JM, Cullen JM, Hartlage AS, Chiriboga L, Ghoshal K, Lipkin WI, Bukh J, Scheel TKH, Kapoor A, Rice CM.

Science. 2017 Jul 14;357(6347):204-208. doi: 10.1126/science.aal1962.

4.

The Strange, Expanding World of Animal Hepaciviruses.

Hartlage AS, Cullen JM, Kapoor A.

Annu Rev Virol. 2016 Sep 29;3(1):53-75. Review.

5.

The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.

Hartlage AS, Liu T, Patton JT, Garman SL, Zhang X, Kurt H, Lozanski G, Lustberg ME, Caligiuri MA, Baiocchi RA.

Cancer Immunol Res. 2015 Jul;3(7):787-94. doi: 10.1158/2326-6066.CIR-14-0242. Epub 2015 Mar 3.

6.

PTEN is a negative regulator of NK cell cytolytic function.

Briercheck EL, Trotta R, Chen L, Hartlage AS, Cole JP, Cole TD, Mao C, Banerjee PP, Hsu HT, Mace EM, Ciarlariello D, Mundy-Bosse BL, Garcia-Cao I, Scoville SD, Yu L, Pilarski R, Carson WE 3rd, Leone G, Pandolfi PP, Yu J, Orange JS, Caligiuri MA.

J Immunol. 2015 Feb 15;194(4):1832-40. doi: 10.4049/jimmunol.1401224. Epub 2015 Jan 16.

Supplemental Content

Loading ...
Support Center